SCM
TVRD

Sterling Capital Management’s Tvardi Therapeutics TVRD Stock Holding History

Sterling Capital Management’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-162
Closed -$515 – 3448
2026
Q1 		$515 Sell
162
-130
-45% -$509 ﹤0.01% 3153
2025
Q4 		$1.26K Buy
292
+3
+1% +$27 ﹤0.01% 3123
2025
Q3 		$11.3K Buy
289
+207
+252% +$5.89K ﹤0.01% 2425
2025
Q2 		$1.91K Buy
+82
New +$1.94K ﹤0.01% 2927

Other funds holding TVRD

SPC
Slate Path Capital New York $7.22B AUM 110.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AFG
American Financial Group Cincinnati, Ohio $284M AUM 12.01% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $15.3B AUM 40.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DWAM
Duncan Williams Asset Management Memphis, Tennessee $444M AUM 24.78% 1-Year Est. Return

Sterling Capital Management's TVRD Position: Q2 2026 in Review

Sterling Capital Management sold out of Tvardi Therapeutics (TVRD) in Q2 2026, closing a stake of 162 shares — an estimated $515 sold.

Sterling Capital Management first reported a position in TVRD in Q2 2025 and held it in 4 quarters. The position peaked at $11.3K in Q3 2025. 58 funds tracked by Wall St. Rank hold TVRD as of Q2 2026.

  • Sterling Capital Management reported no remaining Tvardi Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Sterling Capital Management sold 162 Tvardi Therapeutics shares in Q2 2026, an estimated $515.
  • Sterling Capital Management first reported a position in Tvardi Therapeutics in Q2 2025 and held it in 4 quarters.
  • Sterling Capital Management's Tvardi Therapeutics position peaked at $11.3K in Q3 2025.
  • 58 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.